Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jianjie Ma
Ohio State University, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
The Ohio State University
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Ma had established a company, TRIMedicine, Inc., to commercialize intellectual property involving MG53, which the researcher invented while a faculty member at the Robert Wood Johnson School of Medicine. As the Ohio State University Conflict of Interest Advisory Committee understands, the researcher continues to explore the basic science of MG53 under this NIH grant, entitled “MG53-Mediated Membrane Repair in Muscle Physiology and Disease”, awarded to the Ohio State University.
MG53-Mediated Membrane Repair in Muscle Physiology and Disease
A major challenge in the field of regenerative medicine is developing novel therapeutic approaches to facilitate recovery of injury to skeletal muscle. This project originates from our recent discovery of MG53 as an essential component of the acute membrane repair machinery in muscle cells. Our research and development effort over the past three years have established several key findings that support the feasibility of our goal of targeting MG53-mediated membrane repair in muscle physiology and disease, in particular with the identification of an MG53-interacting protein as a key player for the assembly of the membrane repair patch. The studies proposed here present a unique opportunity to advance the field of regenerative medicine and to make significant progress in translating MG53 and PTRF into therapeutic agents for treatment or prevention of muscular dystrophy.
Filed on December 27, 2012.
Tell us what you know about Jianjie Ma's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jianjie Ma filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jianjie Ma | Ohio State University | Conflict of Interest | TRIM-edicine, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.